Ergomed plc Board appointment (1615T)
July 02 2018 - 2:00AM
UK Regulatory
TIDMERGO
RNS Number : 1615T
Ergomed plc
02 July 2018
PRESS RELEASE
Board appointment
Ergomed strengthens Management Team and Board with appointment
of Stuart Jackson as Chief Financial Officer
London, UK - 2 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or
the "Company") a company focused on providing specialised services
to the pharmaceutical industry, today announces a change to its
Board and management team with the appointment of Stuart Jackson as
Chief Financial Officer with immediate effect.
Stuart brings with him 20 years' experience at Chief Financial
Officer level, having managed companies on the London, NASDAQ and
Oslo Stock Exchanges. He has significant international experience
in early stage and growth companies as well as managing significant
and complex change projects. Stuart's experience has been gained
primarily in the energy and technology/telecommunications sectors
where consistent project service delivery across a number of
geographies has been a key feature of business success.
He was Chief Financial Officer at Acergy SA responsible for the
financial restructuring of the business and implementation of the
new business strategy which took Acergy from $0.1bn to $6.0bn
market capitalisation over a four year period. More recently he was
Chief Financial Officer at CEONA, a Goldman Sachs Capital Partners
group of companies, where he was responsible for the early stage
set-up and growth of the business and Bibby Offshore Holdings
Limited where, as Chief Financial Officer, he also managed the
strategic development and M&A activities and oversaw its recent
recapitalisation.
Stephen Stamp, Chief Executive Officer of Ergomed commented:
"Stuart brings to Ergomed a strong track record of delivery within
project and service related businesses on an international scale.
His experience in non-healthcare services businesses will provide a
broader perspective to our project delivery and he will play an
integral role in enhancing the strong foundations of Ergomed as we
seek to deliver our strategy of taking a market leading positon. I
very much look forward to working closely with Stuart in the next
stage of our exciting development."
Peter George, Chairman of Ergomed commented: "I am very pleased
to welcome Stuart to the Ergomed plc board. His expertise and
experience across a broad range of businesses will be invaluable as
we continue to grow our services and expand into new related
areas."
Stuart holds a BSc in Accounting & Financial Management from
Loughborough University of Technology and he is a Fellow of the
Chartered Institute of Management Accountants. He has a beneficial
holding of 1,845 ordinary shares in the Company.
Save as disclosed below, in relation to current and prior
directorships, Ergomed confirms that there are no further
disclosures to be made in relation to Rule 17 of paragraph (g) of
Schedule Two of the AIM Rules for Companies in respect of Stuart
Jackson's appointment.
Mr Stuart Robert Jackson, aged 58, currently holds and has held
the following directorships in the past five years:
Current directorships: Amava Resorts Pty
Key Energy Finance Limited
Tortuga Energy Services Limited
Directorships in the past Bibby Offshore Holdings Limited
five years: Bibby Offshore Services Plc
Bibby Subsea Inc.
Bibby Subsea Rov
Ceona Chartering (UK) Limited
Ceona Contracting (UK) Limited
Ceona Equipment Limited
Ceona Holding Ltd
Ceona Investments Limited
Ceona Pte. Ltd.
Ceona Services (UK) Limited
Ceona Ship 1 Limited
Ceona Ship 2 Limited
Ceona Ship 3 Limited
Ceona Ship Holdings Limited
Newco 987 Limited
Oig Giant I Pte. Ltd.
Oig Giant Ii Pte. Ltd.
Project Development International
Limited
Tartaruga Limited
-----------------------------------
- Ends -
Enquiries:
Ergomed plc Tel: +44 (0) 1483 503
205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited Tel: +44 (0) 20 7260
1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black (Joint Broker)
N+1 Singer Tel: +44 (0) 20 7496
3000
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for Tel: +44 (0) 20 3709
UK enquiries 5700
Chris Gardner / Mary-Jane Elliott ergomed@Consilium-comms.com
Ivar Milligan / Olivia Manser
MC Services - for Continental European Tel: +49 211 5292 5222
enquiries
Anne Hennecke
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing,
profitable services offering encompasses a complete suite of
specialist pharmacovigilance solutions, integrated under the
PrimeVigilance brand, in addition to a full range of high quality
contract research and trial management services (CRO). Leveraging
its CRO expertise, Ergomed also has a drug development portfolio of
co-development partnerships and wholly-owned programmes. For
further information, visit: http://ergomedplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGUBAMUPRGMG
(END) Dow Jones Newswires
July 02, 2018 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024